pilsicainide has been researched along with procainamide in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Sen, S; Sinha, N | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Arita, M; Kiyosue, T; Sato, T; Wu, B | 1 |
| Fujiki, A; Inoue, H; Tani, M; Yoshida, S | 1 |
| Fujiki, A; Hayashi, H; Inoue, H; Mizumaki, K; Nagasawa, H; Usui, M | 1 |
| Izumi, T; Kitano, Y; Moriguchi, M; Niwano, S | 1 |
1 review(s) available for pilsicainide and procainamide
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
1 trial(s) available for pilsicainide and procainamide
| Article | Year |
|---|---|
Electrophysiologic mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline, pilsicainide, disopyramide, procainamide) in induction of atrioventricular re-entrant tachycardia.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Disopyramide; Electrophysiology; Female; Heart Conduction System; Humans; Imidazoles; Lidocaine; Male; Middle Aged; Procainamide; Tachycardia, Atrioventricular Nodal Reentry; Wolff-Parkinson-White Syndrome | 1996 |
5 other study(ies) available for pilsicainide and procainamide
| Article | Year |
|---|---|
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.
Topics: 2,4-Dinitrophenol; Action Potentials; Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Dinitrophenols; Disopyramide; Flecainide; Glyburide; Guinea Pigs; Heart Ventricles; Imidazoles; Lidocaine; Mexiletine; Myocardium; Piperidines; Potassium; Procainamide; Pyridines | 1992 |
ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainide; Follow-Up Studies; Heart Rate; Humans; Lidocaine; Male; Middle Aged; Procainamide; Recurrence; Tachycardia, Paroxysmal; Tachycardia, Ventricular; Wolff-Parkinson-White Syndrome | 1999 |
Transient appearance of antegrade conduction via an AV accessory pathway caused by atrial fibrillation in a patient with intermittent Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Electrocardiography; Heart Conduction System; Humans; Injections, Intravenous; Lidocaine; Male; Middle Aged; Procainamide; Wolff-Parkinson-White Syndrome | 2000 |